Takeda Reports China NMPA Approval Of LIVTENCITY (maribavir) For Treatment Of Adults With Post-Transplant Cytomegalovirus (CMV) Refractory To Prior Therapies
Portfolio Pulse from Benzinga Newsdesk
Takeda has received approval from China's NMPA for LIVTENCITY (maribavir) to treat adults with post-transplant CMV refractory to prior therapies. LIVTENCITY is the first and only CMV-specific UL97 protein kinase inhibitor in China for this indication and was granted Breakthrough Therapy Designation by the CDE in 2021.
December 21, 2023 | 9:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Takeda's LIVTENCITY has been approved by China's NMPA for treating CMV in post-transplant adults, marking a significant regulatory milestone for the company in the Chinese market.
The approval of LIVTENCITY in China is likely to have a positive short-term impact on Takeda's stock price as it opens up a new market for the drug, which is the first of its kind for this indication in China. The Breakthrough Therapy Designation suggests a high unmet medical need and potential for rapid adoption.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100